3-(4-Chlorophenoxy)-1,2-propanediol

Catalog No. :
ACREGA831
CAS No. :
104-29-0
Molecular Formula :
C9H11ClO3
Molecular Weight :
202.64

IUPAC Name:3-(4-chlorophenoxy)propane-1,2-diol

3-(4-Chlorophenoxy)-1,2-propanediol structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
500g98%$62.00Login to see priceIn stockInquiry
1000g98%$103.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name3-(4-Chlorophenoxy)-1,2-propanediol
IUPAC Name3-(4-chlorophenoxy)propane-1,2-diol
MDL No.MFCD00021990
Molecular FormulaC9H11ClO3
Molecular Weight202.64
SMILESOCC(O)COC1=CC=C(Cl)C=C1
InChI KeyMXOAEAUPQDYUQM-UHFFFAOYSA-N
SynonymDTXCID5028954 | NCGC00160584-01 | SR-01000944964-1 | CHLORPHENESIN [WHO-DD] | Chlorphenesine (INN-French) | Z995094004 | CS-0017448 | D71194 | DTXSID0049028 | 3-(4-chlorophenoxy)propane-1,2-diol | CHLORPHENESIN (MART.) | Maybridge1_000170 | MixCom1_000324
CAS No.104-29-0
PubChem CID7697

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302-H312-H315-H319-H332-H335
Precautionary Statement(s)
P261-P280-P305+P351+P338

Synthetic Route by SureRoute

1. ACREGA831 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACVAGD263 route compound structure diagram
    ACVAGD2631193-00-6 In Stock
  4. Then
  5. ACREGA831 route product structure diagram
    ACREGA831104-29-0 In Stock
Inquiry

2. ACREGA831 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACVAGD263 route compound structure diagram
    ACVAGD2631193-00-6 In Stock
  4. Plus
  5. ACABCJ598 route compound structure diagram
    ACABCJ59852193-54-1 In Stock
  6. Then
  7. ACREGA831 route product structure diagram
    ACREGA831104-29-0 In Stock
Inquiry

Comments (0)